Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.

@article{Ricciardelli1998ElevatedLO,
  title={Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.},
  author={Carmela Ricciardelli and Keiko Mayne and Pamela J Sykes and Wendy A. Raymond and Kieran McCaul and Villis R. Marshall and David J. Horsfall},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1998},
  volume={4 4},
  pages={963-71}
}
Patients with clinically localized prostate cancer who might be cured by aggressive management are not easily identified using current clinical information. Additional, more accurate, biomarkers of tumor behavior need to be identified to improve clinical outcome. Our previous studies indicated that the concentration of the glycosaminoglycan chondroitin sulfate in prostatic stroma might be a useful biomarker of disease progression in early-stage prostate cancer. In this study, two chondroitin… CONTINUE READING